Tharimmune, Inc. | WebDisclosure

Basculer en Français

10184	Companies
209580	Keywords
139721	Articles
111117	Press releases

Home
Companies
Tharimmune, Inc.

PRESS RELEASE

published on 05/19/2025 at 14:01, 10 months 21 days ago

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Tharimmune, Inc. appoints James Gordon Liddy as strategic advisor for TH104 development, targeting high-potency opioid exposure. FDA feedback positive for prophylaxis indication

Tharimmune Inc. FDA Feedback High-Potency Opioids James Gordon Liddy TH104 Development
BRIEF

published on 05/06/2025 at 14:06, 11 months 3 days ago

Tharimmune Reports Positive Phase 1 Results for TH104

Tharimmune Inc. FDA Feedback Phase 1 Study Opioid Prophylaxis TH104 Buccal Film
BRIEF

published on 05/06/2025 at 14:06, 11 months 3 days ago

Tharimmune annonce des résultats positifs de phase 1 pour le TH104

Tharimmune Inc. Étude De Phase 1 Commentaires De La FDA Prophylaxie Aux Opioïdes Film Buccal TH104
PRESS RELEASE

published on 05/06/2025 at 14:01, 11 months 3 days ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025

Tharimmune Inc. TH104 Buccal Film Pharmacokinetic Study Opioid Prophylaxis
BRIEF

published on 05/01/2025 at 14:06, 11 months 8 days ago

Le TH104 de Tharimmune sera présenté lors de conférences médicales importantes

Biopharmaceutique TH104 Tharimmune DDW 2025 EASL 2025
BRIEF

published on 05/01/2025 at 14:06, 11 months 8 days ago

Tharimmune's TH104 to Be Presented at Notable Medical Conferences

TH104 Biopharmaceutical Tharimmune DDW 2025 EASL 2025
PRESS RELEASE

published on 05/01/2025 at 14:01, 11 months 8 days ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Tharimmune, Inc. announces presentation of clinical data on lead drug TH104 at DDW and EASL Annual Meetings in May 2025, addressing unmet medical needs in immunology & inflammation

Tharimmune Inc. TH104 Clinical Data Immunology Unmet Medical Needs
BRIEF

published on 04/30/2025 at 14:06, 11 months 9 days ago

Tharimmune élargit son conseil d'administration avec de nouvelles nominations

Stratégie De Croissance Biopharmaceutique Direction Nominations Au Conseil D'administration Tharimmune
BRIEF

published on 04/30/2025 at 14:06, 11 months 9 days ago

Tharimmune Expands Board with New Appointments

Growth Strategy Biopharmaceutical Leadership Board Appointments Tharimmune
PRESS RELEASE

published on 04/30/2025 at 14:01, 11 months 9 days ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Tharimmune, Inc. appoints Clay Kahler and Gary Stetz to its Board of Directors, expanding to 9 members. Kahler brings life sciences expertise while Stetz contributes financial acumen

Board Of Directors Financial Expertise Tharimmune Clay Kahler Gary Stetz

Accesswire

Published on 04/10/2026 at 02:15, 3 hours 33 minutes ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 4 hours 43 minutes ago

Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 5 hours 48 minutes ago

Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 6 hours 33 minutes ago

Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/09/2026 at 23:05, 6 hours 43 minutes ago

Caldwell Reports Second Quarter Results

View all ACCESSWIRE

EQS Group

Published on 04/09/2026 at 22:00, 7 hours 48 minutes ago

Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 8 hours 46 minutes ago

GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 21:01, 8 hours 46 minutes ago

GEVELOT S.A.: COMMUNIQUE ARRETE DES COMPTES 2025
Published on 04/09/2026 at 20:03, 9 hours 44 minutes ago

Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:45, 11 hours 3 minutes ago

EUROPLASMA: Tirage de 200 obligations convertibles en actions nouvelles pour un montant nominal de 1M€

Les Echos

Published on 04/09/2026 at 21:49, 7 hours 58 minutes ago

Résultats 2025 consolidés de NSC Groupe
Published on 04/09/2026 at 20:00, 9 hours 48 minutes ago

SMTPC - Communiqué sur le Chiffre d'affaires du 1er trimestre 2026
Published on 04/09/2026 at 18:35, 11 hours 13 minutes ago

Mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 30 avril 2026
Published on 04/09/2026 at 18:35, 11 hours 13 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 18:00, 11 hours 48 minutes ago

i2S : Chiffre d'Affaires T1 2026

View all LES ECHOS COMFI WIRE